Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before Long
Verona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like ...
Verona Pharma initiated with a Buy at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Verona Pharma (NASDAQ:VRNA) Price Target Raised to $74.00
Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company ...
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
MT Newswires on MSN3d
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.34% to 1,316.18 on the S&P Europe Select ADR Index. From continental Europe, the ...
Verona posts early sales figures for Q4 and 2024
Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...